ECKERT & ZIEGLER STRAHLEN- UND MEDIZINTECHNIK AG

(EUZ)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Eckert & Ziegler Strahlen und Medizintechnik : Hauck & Aufhńuser

09/07/2021 | 04:32am EDT

Eckert & Ziegler AG

Germany - High-tech Engineering

Buy (old: Buy)

07-September-21

Price target: EUR 172.00 (old: EUR 120.50)

Aliaksandr Halitsa

Analyst

Price:

EUR 129.90

Next result:

Q3 09.11.21

Bloomberg:

EUZ GR

Market cap:

EUR 2,645.8 m

aliaksandr.halitsa@ha-ib.de

Reuters:

EUZG.DE

Enterprise Value:

EUR 2,563.4 m

Tel.: +49 40 414 3885 83

Global radioisotope competence as a competitive advantage

As the nuclear medicine market and specifically radioligand therapies - a highly effective cancer treatment modality comprising radioactive diagnostic and therapeutic agents - are transitioning from a niche into a mainstream, the existing growth opportunities expand while entirely new ones emerge.

Thanks to its deep expertise and one-stop-shop offering coupled with investments into global capacities and further capabilities, EUZ is the go-topartner for pharma companies looking for a secure supply of medical radioisotopes and a whole range of auxiliary services, including infrastructure build out, CMO services, etc. Below are the most exciting opportunities that we have re-evaluated in our SOTP resulting in a higher PT:

  • Earlier, EUZ acquired a clinically well-researched, yet commercially overlooked early stage asset in the radioligand therapies space (Pentixa). Thanks to extensive body of prior research, the diagnostic agent is expedited directly into Phase 3 and could see a significant value inflection as soon as 2023/24. With its potential to significantly improve the standard of care in treatment of multiple myeloma, AML and non-Hodgkin lymphoma with a total incidence of 290k p.a., the diagnostic alone could be worth $ 1bn+ upon receiving an approval by 2024. Naturally, there should be a lot of interest in this compound from big pharma looking to establish its presence in this field. In 2017, Novartis paid $ 3.9bn for AAA following the approval of its radioligand therapy Lutathera targeting neuroendocrine tumors with incidence rate of c. 9k p.a.
  • China and CMO business represent significant, yet barely tapped growth opportunities. First, as China continues to invest strongly into its healthcare system with many companies pioneering innovative isotope-basedtherapies, EUZ will be able to leverage its existing offering in a gigantic market. Second, the CMO opportunity is increasingly taking shape with two qualified inquiries from big pharma for major CMO contracts.
  • Still at an early stage, yet not less exciting is the Actinium-225 (Ac-225)opportunity. Through its waste management business, EUZ has accumulated the largest European stock of Radium-226(Ra-226) due for a disposal. This liability turned into a significant asset, as Ac-225 came to prominence as the "next Lutetium-177" perfectly fitting for the next wave of radioligand therapies. NB: Ra-226 is a precursor of Ac-225.

BUY with a new PT of € 172 (old: € 120) based on SOTP.

Y/E 31.12 (EUR m)

2017

2018

2019

2020

2021E

2022E

2023E

Sales

138.6

168.7

178.5

176.1

179.6

226.3

281.3

Sales growth

16 %

22 %

6 %

-1 %

2 %

26 %

24 %

EBITDA

26.6

32.0

43.1

44.8

50.5

66.6

90.5

EBIT

18.0

23.4

32.1

33.7

39.4

55.5

80.5

Net income

14.7

16.1

22.0

22.9

26.9

38.3

55.9

Net debt

-56.0

-54.1

-78.9

-88.6

-96.9

-117.8

-146.2

Net gearing

-49.8 % -44.1 %

-57.1 % -59.9 %

-59.6 % -61.3 %

-62.4 %

Net Debt/EBITDA

0.0

0.0

0.0

0.0

0.0

0.0

0.0

EPS pro forma

0.57

3.12

1.06

1.04

1.31

1.86

2.72

CPS

0.89

0.64

1.46

1.28

1.09

1.25

1.88

DPS

0.80

1.20

0.35

0.35

0.44

0.62

0.90

Dividend yield

0.6 %

0.9 %

0.3 %

0.3 %

0.3 %

0.5 %

0.7 %

Gross profit margin

46.1 %

44.1 %

48.8 %

49.1 %

50.5 %

52.5 %

53.1 %

EBITDA margin

19.2 %

18.9 %

24.2 %

25.4 %

28.1 %

29.4 %

32.2 %

EBIT margin

13.0 %

13.9 %

18.0 %

19.1 %

21.9 %

24.5 %

28.6 %

ROCE

13.8 %

17.6 %

22.5 %

22.9 %

26.2 %

26.3 %

27.4 %

EV/sales

18.7

15.4

14.4

14.6

14.3

11.2

8.9

EV/EBITDA

97.5

81.2

59.7

57.4

50.8

38.2

27.8

EV/EBIT

144.3

111.0

80.3

76.3

65.1

45.8

31.2

PER

227.6

160.1

119.0

121.5

95.8

66.5

47.3

Adjusted FCF yield

0.5 %

0.7 %

0.9 %

1.0 %

1.1 %

1.6 %

2.3 %

Source: Company data, Hauck & Aufhäuser Close price as of: 06.09.2021

Source: Company data, Hauck & Aufhäuser

High/low 52 weeks:

126.00 / 39.24

Price/Book Ratio:

15.9

Relative performance (SDAX):

3 months

33.9 %

6 months

105.1 %

12 months

162.9 %

Changes in estimates

Sales

EBIT

EPS

2021

old:

183.6

39.4

1.31

-2.2%

-

-

2022

old:

226.3

55.5

1.86

-

-

-

2023

old:

281.3

80.5

2.72

-

-

-

Key share data:

Number of shares: (in m pcs)

20.6

Authorised capital: (in € m)

0.6

Book value per share: (in €)

7.9

Ø trading volume: (12 months)

20,453

Major shareholders:

Free float

67.8 %

Founders

32.2 %

Eckert & Ziegler AG

0.1 %

Company description:

Produces and markets a wide range of industrial and medical applications featuring radioactive isotopes, including prostate seed implants, calibration standards and radiation afterloaders.

Please refer to important disclosures at the end of the report

Eckert & Ziegler AG

Fair Value Composition (€ per share)

Source: H&A

Major changes:

CMO (old): € 26 per share / reflects stronger visibility of the CMO revenue potential with two qualified inquiries from big pharma.

PentixaPharm (old): € 6 per share / reflects improving visibility on the development timeline and its game-changing nature for the treatment of a range of hematologic tumors.

Other development projects (old): € 0 per share / pricing in combined € 200m sales at 25% EBIT margin by 2030 generated with Bayer (Thorium conjugates project), OncoSil (pancreatic cancer treatment with phosphorus-32), myelo (anti-radiation pill; constituent of the Bayer Pharmaceuticals incubator).

2

Hauck & Aufhäuser Privatbankiers AG

Eckert & Ziegler AG

Financials

Profit and loss (EUR m)

2017

2018

2019

2020

2021E

2022E

2023E

Sales

138.6

168.7

178.5

176.1

179.6

226.3

281.3

Sales growth

15.7 %

21.7 %

5.8 %

-1.3 %

2.0 %

26.0 %

24.3 %

Cost of sales

74.8

94.4

91.5

89.6

88.9

107.5

131.9

Gross profit

63.9

74.3

87.0

86.5

90.7

118.8

149.3

Sales and marketing

20.0

23.3

22.9

21.7

22.3

26.0

28.1

General and administration

23.9

26.9

27.6

28.1

27.3

33.5

38.3

Research and development

0.0

0.0

0.0

0.0

0.0

0.0

0.0

Other operating income

3.8

3.5

2.8

5.8

5.8

5.8

5.8

Other operating expenses

4.5

4.5

7.1

7.2

7.5

9.5

8.2

Unusual or infrequent items

-1.2

0.2

-0.2

-1.6

0.0

0.0

0.0

EBITDA

26.6

32.0

43.1

44.8

50.5

66.6

90.5

Depreciation

8.6

8.6

11.1

11.1

11.1

11.1

10.0

EBITA

18.0

23.4

32.1

33.7

39.4

55.5

80.5

Amortisation of goodwill

0.0

0.0

0.0

0.0

0.0

0.0

0.0

Amortisation of intangible assets

0.0

0.0

0.0

0.0

0.0

0.0

0.0

Impairment charges

0.0

0.0

0.0

0.0

0.0

0.0

0.0

EBIT (inc revaluation net)

18.0

23.4

32.1

33.7

39.4

55.5

80.5

Interest income

0.3

0.2

0.3

0.2

0.2

0.2

0.2

Interest expenses

0.9

0.7

1.1

1.2

1.2

1.2

1.2

Other financial result

0.0

0.0

0.0

0.0

0.0

0.0

0.0

Financial result

-0.6

-0.5

-0.8

-0.9

-0.9

-0.9

-0.9

Recurring pretax income from continuing operations

17.3

22.9

31.2

32.7

38.4

54.6

79.6

Extraordinary income/loss

0.0

0.0

0.0

0.0

0.0

0.0

0.0

Earnings before taxes

17.3

22.9

31.2

32.7

38.4

54.6

79.6

Taxes

5.3

6.0

8.8

9.6

11.3

16.1

23.4

Net income from continuing operations

12.0

16.9

22.5

23.1

27.1

38.5

56.2

Result from discontinued operations (net of tax)

3.1

0.0

0.0

0.0

0.0

0.0

0.0

Net income

15.1

16.9

22.5

23.1

27.1

38.5

56.2

Minority interest

0.4

0.8

0.5

0.2

0.2

0.2

0.2

Net profit (reported)

14.7

16.1

22.0

22.9

26.9

38.3

55.9

Average number of shares

20.5

20.5

20.5

20.6

20.6

20.6

20.6

EPS reported

0.72

0.79

1.07

1.11

1.31

1.86

2.72

Profit and loss (common size)

2017

2018

2019

2020

2021E

2022E

2023E

Sales

100.0 %

100.0 %

100.0 %

100.0 %

100.0 %

100.0 %

100.0 %

Cost of sales

53.9 %

55.9 %

51.2 %

50.9 %

49.5 %

47.5 %

46.9 %

Gross profit

46.1 %

44.1 %

48.8 %

49.1 %

50.5 %

52.5 %

53.1 %

Sales and marketing

14.4 %

13.8 %

12.8 %

12.3 %

12.4 %

11.5 %

10.0 %

General and administration

17.3 %

15.9 %

15.4 %

15.9 %

15.2 %

14.8 %

13.6 %

Research and development

0.0 %

0.0 %

0.0 %

0.0 %

0.0 %

0.0 %

0.0 %

Other operating income

2.7 %

2.1 %

1.6 %

3.3 %

3.2 %

2.5 %

2.0 %

Other operating expenses

3.2 %

2.6 %

4.0 %

4.1 %

4.2 %

4.2 %

2.9 %

Unusual or infrequent items

neg.

0.1 %

neg.

neg.

0.0 %

0.0 %

0.0 %

EBITDA

19.2 %

18.9 %

24.2 %

25.4 %

28.1 %

29.4 %

32.2 %

Depreciation

6.2 %

5.1 %

6.2 %

6.3 %

6.2 %

4.9 %

3.6 %

EBITA

13.0 %

13.9 %

18.0 %

19.1 %

21.9 %

24.5 %

28.6 %

Amortisation of goodwill

0.0 %

0.0 %

0.0 %

0.0 %

0.0 %

0.0 %

0.0 %

Amortisation of intangible assets

0.0 %

0.0 %

0.0 %

0.0 %

0.0 %

0.0 %

0.0 %

Impairment charges

0.0 %

0.0 %

0.0 %

0.0 %

0.0 %

0.0 %

0.0 %

EBIT (inc revaluation net)

13.0 %

13.9 %

18.0 %

19.1 %

21.9 %

24.5 %

28.6 %

Interest income

0.2 %

0.1 %

0.2 %

0.1 %

0.1 %

0.1 %

0.1 %

Interest expenses

0.6 %

0.4 %

0.6 %

0.7 %

0.7 %

0.5 %

0.4 %

Other financial result

0.0 %

0.0 %

0.0 %

0.0 %

0.0 %

0.0 %

0.0 %

Financial result

neg.

neg.

neg.

neg.

neg.

neg.

neg.

Recurring pretax income from continuing operations

12.5 %

13.6 %

17.5 %

18.6 %

21.4 %

24.1 %

28.3 %

Extraordinary income/loss

0.0 %

0.0 %

0.0 %

0.0 %

0.0 %

0.0 %

0.0 %

Earnings before taxes

12.5 %

13.6 %

17.5 %

18.6 %

21.4 %

24.1 %

28.3 %

Tax rate

30.7 %

26.2 %

28.1 %

29.4 %

29.4 %

29.4 %

29.4 %

Net income from continuing operations

8.7 %

10.0 %

12.6 %

13.1 %

15.1 %

17.0 %

20.0 %

Result from discontinued operations (net of tax)

2.2 %

0.0 %

0.0 %

0.0 %

0.0 %

0.0 %

0.0 %

Net income

10.9 %

10.0 %

12.6 %

13.1 %

15.1 %

17.0 %

20.0 %

Minority interest

0.3 %

0.4 %

0.3 %

0.1 %

0.1 %

0.1 %

0.1 %

Net profit (reported)

10.6 %

9.6 %

12.3 %

13.0 %

15.0 %

16.9 %

19.9 %

Source: Company data, Hauck & Aufhäuser

3

Hauck & Aufhäuser Privatbankiers AG

Eckert & Ziegler AG

Balance sheet (EUR m)

2017

2018

2019

2020

2021E

2022E

2023E

Intangible assets

51.4

52.5

51.9

41.4

41.4

41.4

41.4

Property, plant and equipment

33.8

36.9

40.0

38.0

41.9

38.2

34.7

Financial assets

3.2

3.5

5.2

8.0

8.0

8.0

8.0

FIXED ASSETS

88.5

93.0

97.1

87.4

91.3

87.6

84.1

Inventories

26.8

28.8

31.2

33.6

36.6

43.5

54.1

Accounts receivable

24.3

28.3

29.5

28.2

31.5

39.7

49.3

Other current assets

10.9

14.9

26.6

42.3

42.3

42.3

42.3

Liquid assets

57.7

54.2

78.9

88.6

96.9

117.8

146.2

Deferred taxes

8.8

9.9

10.9

11.9

0.0

0.0

0.0

Deferred charges and prepaid expenses

0.0

0.0

0.0

0.0

0.0

0.0

0.0

CURRENT ASSETS

128.5

136.1

177.1

204.6

207.3

243.3

291.9

TOTAL ASSETS

217.0

229.1

274.2

292.0

298.6

330.9

375.9

SHAREHOLDERS EQUITY

112.3

122.6

138.2

147.8

162.6

192.0

234.1

MINORITY INTEREST

5.2

1.2

1.2

1.1

1.1

0.0

0.0

Long-term debt

0.0

0.0

0.0

0.0

0.0

0.0

0.0

Provisions for pensions and similar obligations

11.7

11.4

13.5

14.4

14.4

14.4

14.4

Other provisions

48.7

55.1

66.4

70.5

64.8

66.1

67.4

Non-current liabilities

60.4

66.5

79.9

84.9

79.3

80.6

81.9

short-term liabilities to banks

1.7

0.0

0.0

0.0

0.0

0.0

0.0

Accounts payable

4.5

6.5

4.5

5.0

6.1

7.4

9.0

Advance payments received on orders

5.9

4.1

12.0

8.6

8.6

8.6

8.6

Other liabilities (incl. from lease and rental contracts)

17.3

17.4

35.6

42.3

42.3

42.3

42.3

Deferred taxes

6.4

7.1

2.8

2.2

0.0

0.0

0.0

Deferred income

3.3

3.6

0.0

0.0

0.0

0.0

0.0

Current liabilities

39.1

38.8

54.9

58.2

57.0

58.3

60.0

TOTAL LIABILITIES AND SHAREHOLDERS EQUITY

217.0

229.1

274.2

292.0

300.0

330.9

375.9

Balance sheet (common size)

2017

2018

2019

2020

2021E

2022E

2023E

Intangible assets

23.7 %

22.9 %

18.9 %

14.2 %

13.8 %

12.5 %

11.0 %

Property, plant and equipment

15.6 %

16.1 %

14.6 %

13.0 %

14.0 %

11.5 %

9.2 %

Financial assets

1.5 %

1.5 %

1.9 %

2.7 %

2.7 %

2.4 %

2.1 %

FIXED ASSETS

40.8 %

40.6 %

35.4 %

29.9 %

30.4 %

26.5 %

22.4 %

Inventories

12.3 %

12.6 %

11.4 %

11.5 %

12.2 %

13.2 %

14.4 %

Accounts receivable

11.2 %

12.4 %

10.8 %

9.7 %

10.5 %

12.0 %

13.1 %

Other current assets

5.0 %

6.5 %

9.7 %

14.5 %

14.1 %

12.8 %

11.3 %

Liquid assets

26.6 %

23.7 %

28.8 %

30.3 %

32.3 %

35.6 %

38.9 %

Deferred taxes

4.1 %

4.3 %

4.0 %

4.1 %

0.0 %

0.0 %

0.0 %

Deferred charges and prepaid expenses

0.0 %

0.0 %

0.0 %

0.0 %

0.0 %

0.0 %

0.0 %

CURRENT ASSETS

59.2 %

59.4 %

64.6 %

70.1 %

69.1 %

73.5 %

77.6 %

TOTAL ASSETS

100.0 %

100.0 %

100.0 %

100.0 %

99.5 %

100.0 %

100.0 %

SHAREHOLDERS EQUITY

51.8 %

53.5 %

50.4 %

50.6 %

54.2 %

58.0 %

62.3 %

MINORITY INTEREST

2.4 %

0.5 %

0.5 %

0.4 %

0.4 %

0.0 %

0.0 %

Long-term debt

0.0 %

0.0 %

0.0 %

0.0 %

0.0 %

0.0 %

0.0 %

Provisions for pensions and similar obligations

5.4 %

5.0 %

4.9 %

4.9 %

4.8 %

4.4 %

3.8 %

Other provisions

22.4 %

24.0 %

24.2 %

24.1 %

21.6 %

20.0 %

17.9 %

Non-current liabilities

27.8 %

29.0 %

29.1 %

29.1 %

26.4 %

24.4 %

21.8 %

short-term liabilities to banks

0.8 %

0.0 %

0.0 %

0.0 %

0.0 %

0.0 %

0.0 %

Accounts payable

2.1 %

2.8 %

1.6 %

1.7 %

2.0 %

2.2 %

2.4 %

Advance payments received on orders

2.7 %

1.8 %

4.4 %

3.0 %

2.9 %

2.6 %

2.3 %

Other liabilities (incl. from lease and rental contracts)

8.0 %

7.6 %

13.0 %

14.5 %

14.1 %

12.8 %

11.3 %

Deferred taxes

3.0 %

3.1 %

1.0 %

0.8 %

0.0 %

0.0 %

0.0 %

Deferred income

1.5 %

1.6 %

0.0 %

0.0 %

0.0 %

0.0 %

0.0 %

Current liabilities

18.0 %

16.9 %

20.0 %

19.9 %

19.0 %

17.6 %

16.0 %

TOTAL LIABILITIES AND SHAREHOLDERS EQUITY

100.0 %

100.0 %

100.0 %

100.0 %

100.0 %

100.0 %

100.0 %

Source: Company data, Hauck & Aufhäuser

4

Hauck & Aufhäuser Privatbankiers AG

Eckert & Ziegler AG

Cash flow statement (EUR m)

2017

2018

2019

2020

2021E

2022E

2023E

Net profit/loss

15.1

16.9

22.5

23.1

27.1

38.5

56.2

Depreciation of fixed assets (incl. leases)

8.6

8.6

11.1

11.1

11.1

11.1

10.0

Amortisation of goodwill

0.0

0.0

0.0

0.0

0.0

0.0

0.0

Amortisation of intangible assets

0.0

0.0

0.0

0.0

0.0

0.0

0.0

Others

5.5

2.8

10.6

4.3

0.0

0.0

0.0

Cash flow from operations before changes in w/c

29.3

28.2

44.1

38.5

38.2

49.6

66.2

Increase/decrease in inventory

-1.7

0.7

-2.2

-2.4

-3.1

-6.9

-10.6

Increase/decrease in accounts receivable

-1.1

-4.0

-1.2

0.1

-3.3

-8.2

-9.6

Increase/decrease in accounts payable

-1.9

2.0

-0.4

0.5

1.1

1.3

1.7

Increase/decrease in other working capital positions

2.2

-5.7

0.0

0.0

0.0

0.0

0.0

Increase/decrease in working capital

-2.5

-7.0

-3.7

-1.7

-5.3

-13.8

-18.5

Cash flow from operating activities

26.8

21.2

40.4

36.8

32.9

35.8

47.7

CAPEX

4.2

6.1

7.3

8.9

15.0

7.3

6.5

Payments for acquisitions

5.5

2.1

0.9

0.0

0.0

0.0

0.0

Financial investments

0.5

0.0

0.0

5.4

0.0

0.0

0.0

Income from asset disposals

15.2

-2.5

2.5

0.9

0.0

0.0

0.0

Cash flow from investing activities

5.1

-10.7

-5.7

-13.3

-15.0

-7.3

-6.5

Cash flow before financing

31.9

10.5

34.7

23.4

17.9

28.5

41.2

Increase/decrease in debt position

-5.3

-1.7

-2.7

-3.0

0.0

0.0

0.0

Purchase of own shares

0.0

8.6

0.0

0.0

0.0

0.0

0.0

Capital measures

0.0

0.0

0.0

0.0

0.0

0.0

0.0

Dividends paid

3.5

4.1

6.2

8.8

7.1

9.0

12.8

Others

-1.2

-0.2

-1.7

-1.2

0.0

0.0

0.0

Effects of exchange rate changes on cash

-0.8

0.6

0.5

-1.9

0.0

0.0

0.0

Cash flow from financing activities

-10.0

-14.6

-10.5

-13.0

-7.1

-9.0

-12.8

Increase/decrease in liquid assets

21.1

-3.5

24.7

8.6

10.8

19.5

28.4

Liquid assets at end of period

57.7

54.2

78.9

87.4

98.2

117.8

146.2

Source: Company data, Hauck & Aufhäuser

Regional split (EUR m)

2017

2018

2019

2020

2021E

2022E

2023E

Domestic

0.0

0.0

0.0

0.0

0.0

0.0

0.0

yoy change

n/a

n/a

n/a

n/a

n/a

n/a

n/a

Rest of Europe

84.9

96.8

110.4

125.9

143.5

163.6

186.5

yoy change

14.0 %

14.0 %

14.0 %

14.0 %

14.0 %

14.0 %

14.0 %

NAFTA

53.0

60.9

70.1

80.6

92.7

106.6

122.5

yoy change

15.0 %

15.0 %

15.0 %

15.0 %

15.0 %

15.0 %

15.0 %

Asia Pacific

15.8

17.9

20.2

22.9

25.8

29.2

33.0

yoy change

13.0 %

13.0 %

13.0 %

13.0 %

13.0 %

13.0 %

13.0 %

Rest of world

-15.1

-7.0

-22.2

-53.1

-82.4

-73.0

-60.7

yoy change

neg.

neg.

neg.

neg.

neg.

neg.

neg.

TTL

138.6

168.7

178.5

176.1

179.6

226.3

281.3

yoy change

15.7 %

21.7 %

5.8 %

-1.3 %

2.0 %

26.0 %

24.3 %

Source: Company data, Hauck & Aufhäuser

5

Hauck & Aufhäuser Privatbankiers AG

This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

Eckert & Ziegler AG published this content on 07 September 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 07 September 2021 08:31:07 UTC.


ę Publicnow 2021
All news about ECKERT & ZIEGLER STRAHLEN- UND MEDIZINTECHNIK AG
05/12Eckert & Ziegler Strahlen- und Medizintechnik AG Reports Earnings Results for the First..
CI
05/12Eckert & Ziegler with Sales Growth in the First Quarter of 2022
EQ
05/12Eckert & Ziegler Strahlen- und Medizintechnik AG Reaffirms Earnings Guidance for the Ye..
CI
05/11Eckert & Ziegler Cooperates with Czech Research Center UJF to Produce Pharmaceutical Al..
EQ
05/11Eckert & Ziegler Cooperates with Czech Research Center UJF to Produce Pharmaceutical Al..
CI
04/12ECKERT & ZIEGLER STRAHLEN UND MEDIZI : Report of the Supervisory Board
PU
04/12ECKERT & ZIEGLER STRAHLEN UND MEDIZI : Proposal on the appropriation of net income
PU
04/11ECKERT & ZIEGLER : Hauck & Aufhauser remains its Buy rating
MD
04/11ECKERT & ZIEGLER STRAHLEN UND MEDIZI : Hauck & Aufhäuser
PU
04/08ECKERT & ZIEGLER : Radboud University Medical Center Netherlands to Image First Patient wi..
EQ
More news
Analyst Recommendations on ECKERT & ZIEGLER STRAHLEN- UND MEDIZINTECHNIK AG
More recommendations
Financials
Sales 2022 205 M 216 M 216 M
Net income 2022 30,7 M 32,3 M 32,3 M
Net cash 2022 55,7 M 58,7 M 58,7 M
P/E ratio 2022 28,8x
Yield 2022 1,17%
Capitalization 890 M 938 M 938 M
EV / Sales 2022 4,07x
EV / Sales 2023 3,91x
Nbr of Employees 866
Free-Float 67,1%
Chart ECKERT & ZIEGLER STRAHLEN- UND MEDIZINTECHNIK AG
Duration : Period :
Eckert & Ziegler Strahlen- und Medizintechnik AG Technical Analysis Chart | EUZ | DE0005659700 | MarketScreener
Technical analysis trends ECKERT & ZIEGLER STRAHLEN- UND MEDIZINTECHNIK AG
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Last Close Price 42,90 €
Average target price 152,00 €
Spread / Average Target 254%
EPS Revisions
Managers and Directors
Andreas Eckert Chairman-Executive Board
Wolfgang Maennig Chairman-Supervisory Board
Helmut Grothe Vice Chairman-Supervisory Board
Albert Rupprecht Member-Supervisory Board
Edgar L÷ffler Member-Supervisory Board
Sector and Competitors
1st jan.Capi. (M$)
ECKERT & ZIEGLER STRAHLEN- UND MEDIZINTECHNIK AG-54.41%938
JOHNSON & JOHNSON4.53%470 547
PFIZER, INC.-13.06%288 063
ABBVIE INC.14.31%273 513
ELI LILLY AND COMPANY9.12%271 308
ROCHE HOLDING AG-14.97%263 868